>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
炎症及营养指标与直肠癌新辅助放化疗病理反应及患者预后的相关性研究
作者:王逸君  张碧云  陈乐君  鹿红  马珺  宋威  于大海 
单位:南京中医药大学附属医院 放疗科, 江苏 南京 210029
关键词:直肠肿瘤/放化疗法 预后营养指数 系统性炎症反应 病理反应 预后 
分类号:R735.37
出版年·卷·期(页码):2021·40·第五期(578-585)
摘要:

目的:分析不同的炎症及营养相关指标与直肠癌新辅助放化疗后肿瘤病理反应状态及患者预后的相关性,探讨其临床应用价值。方法:回顾性分析2012年10月至2019年2月在南京中医药大学附属医院接受新辅助放化疗及根治性手术的211例Ⅱ、Ⅲ期直肠癌患者的临床病理资料,依据患者放化疗前1周内血常规和肝肾功能检查结果,计算基线中性粒细胞/淋巴细胞之值(NLR)、血小板/淋巴细胞之值(PLR)、淋巴细胞/单核细胞之值(LMR)及预后营养指数(PNI)。根据患者术后病理结果,基于肿瘤消退分级(TRG)标准评价肿瘤病理反应状态。采用Logistic模型、Kaplan-Meier法、Cox回归模型分析各炎症及营养相关指标与直肠癌新辅助放化疗肿瘤病理反应状态及患者预后的相关性。结果:新辅助放化疗后病理反应(TRG 0~1级)患者共135例(64.0%),非病理反应(TRG 2~3级)患者76例(36.0%)。多因素Logistic回归分析结果显示,基线PNI(OR=1.245,95% CI 1.123~1.380,P<0.001)及癌胚抗原(OR=0.500,95% CI 0.255~0.979,P=0.043)是病理反应状态的独立影响因素。多因素预后分析显示性别、淋巴(ypN)分期、基线NLR及PNI是无病生存期(DFS)的独立影响因素;性别、ypN分期及基线PNI是总生存期(OS)的独立影响因素。分层分析显示ypN阳性患者中高PNI组(PNI>45)5年DFS和OS显著长于低PNI组(无病生存率63.6% vs.48.0%,P=0.002;总生存率69.2% vs.51.9%,P=0.005),而ypN阴性患者中高PNI组与低PNI组预后差异无统计学意义(无病生存率83.2% vs.79.5%,P=0.252;总生存率89.2% vs.85.1%,P=0.299)。结论:基线PNI水平与Ⅱ、Ⅲ期直肠癌新辅助放化疗后肿瘤病理反应状态及患者预后相关,其疗效预测价值优于NLR、PLR及LMR。PNI简单无创、经济有效,可作为临床预后预测指标的补充,值得进一步研究。

Objective: To evaluate the correlation between inflammatory-nutritional biomarkers and pathologic response and prognosis in rectal cancer patients undergoing neoadjuvant chemoradiotherapy, and to explore the clinical value of these biomarkers. Methods: Clinical and pathological data of 211 stage II-III rectal cancer patients treated with neoadjuvant chemoradiotherapy(nCRT) and subsequent surgery between October 2012 and February 2019 were retrospectively analyzed. Neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), lymphocyte-to-monocyte ratio(LMR) and prognostic nutritional index(PNI) were calculated according to routine laboratory data within 1 week prior nCRT. Pathological response was assessed using the tumor regression grade(TRG) system according to postoperative specimen histopathologic examinations. The relationship between inflammatory-nutritional biomarkers and pathologic response and prognosis were evaluated by Logistic regression analysis, Kaplan-Meier method and Cox regression analyses. Results: Totally, 135 patients(64.0%) achieved good-response(TRG 0-1) and 76 patients(36.0%) achieved poor-response(TRG 2-3) after nCRT. Logistic regression analysis identified that PNI(OR=1.245, 95% CI 1.123-1.380,P<0.001) and CEA(OR=0.500, 95% CI 0.255-0.979,P=0.043) were the independent predictors for pathologic response to nCRT. Multivariate analysis identified gender, ypN stage, NLR and PNI were independent prognostic factors for disease-free survival(DFS) and gender, ypN stage and PNI were independent prognostic factors for overall survival(OS). A high PNI(>45) was significantly associated with better DFS and OS in patients with ypN positive subgroup(DFS 63.6% vs. 48.0%, P=0.002; OS 69.2% vs. 51.9%, P=0.005) but not in patients with ypN negative subgroup(DFS 83.2% vs. 79.5%, P=0.252; OS 89.2% vs. 85.1%, P=0.299). Conclusion: Pretreatment PNI is associated with pathologic response and prognosis in rectal cancer patients undergoing nCRT, superior to the established systemic inflammation markers including NLR, PLR and LMR. Its simplicity, noninvasion, low cost and effectiveness make the PNI a promising supplemental tool in predicting and prognosis marker for patients with rectal cancer.

参考文献:

[1] SAUER R,LIERSCH T,MERKEL S,et al.Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer:results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years[J].J Clin Oncol,2012,30(16):1926-1933.
[2] ROH M S,COLANGELO L H,O'CONNELL M J,et al.Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum:NSABP R-03[J].J Clin Oncol,2009,27(31):5124-5130.
[3] MARTIN S T,HENEGHAN H M,WINTER D C.Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer[J].Br J Surg,2012,99(7):918-928.
[4] O'NEILL B D P,BROWN G,HEALD R J,et al.Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer[J].Lancet Oncol,2007,8(7):625-633.
[5] GUNDERSON L L,JESSUP J M,SARGENT D J,et al.Revised TN categorization for colon cancer based on national survival outcomes data[J].J Clin Oncol,2010,28(2):264-271.
[6] PARK Y A,SOHN S K,SEONG J,et al.Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer[J].J Surg Oncol,2006,93(2):145-150.
[7] SAKAI K,KAZAMA S,NAGAI Y,et al.Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions[J].Oncotarget,2014,5(20):9641-9649.
[8] DAHAN L,NORGUET E,ETIENNE-GRIMALDI M C,et al.Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer[J].BMC Cancer,2011,11(1):496.
[9] CECCHIN E,AGOSTINI M,PUCCIARELLI S,et al.Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy[J].Pharmacogenomics J,2011,11(3):214-226.
[10] 江慧洪,王晖,李阿建,等.中性粒细胞/淋巴细胞比值对局部进展期结直肠癌患者预后的影响[J].中华胃肠外科杂志,2017,20(5):550-554.
[11] PINE J K,MORRIS E,HUTCHINS G G,et al.Systemic neutrophil-to-lymphocyte ratio in colorectal cancer:the relationship to patient survival,tumour biology and local lymphocytic response to tumour[J].Br J Cancer,2015,113(2):204-211.
[12] HU B,YANG X R,XU Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J].Clin Cancer Res,2014,20(23):6212-6222.
[13] 李黎,李曙光,闫可,等.外周血淋巴细胞与单核细胞比值变化对食管癌调强放疗预后影响[J].中华放射肿瘤学杂志,2019,28(10):741-745.
[14] NOZOE T,NINOMIYA M,MAEDA T,et al.Prognostic nutritional index:a tool to predict the biological aggressiveness of gastric carcinoma[J].Surg Today,2010,40(5):440-443.
[15] ROELS S,DUTHOY W,HAUSTERMANS K,et al.Definition and delineation of the clinical target volume for rectal cancer[J].Int J Radiat Oncol Biol Phys,2006,65(4):1129-1142.
[16] RYAN R,GIBBONS D,HYLAND J M P,et al.Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J].Histopathology,2005,47(2):141-146.
[17] ONODERA T,GOSEKI N,KOSAKI G.Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients[J].Nihon Geka Gakkai Zasshi,1984,85(9):1001-1005.
[18] DIAKOS C I,CHARLES K A,McMILLAN D C,et al.Cancer-related inflammation and treatment effectiveness[J].Lancet Oncol,2014,15(11):e493-e503.
[19] ABE S,KAWAI K,NOZAWA H,et al.LMR predicts outcome in patients after preoperative chemoradiotherapy for stage II-III rectal cancer[J].J Surg Res,2018,222(5):122-131.
[20] OKUGAWA Y,TOIYAMA Y,OKI S,et al.Feasibility of assessing prognostic nutrition index in patients with rectal cancer who receive preoperative chemoradiotherapy[J].JPEN J Parenter Enteral Nutr,2018,42(6):998-1007.
[21] LI A,HE K,GUO D,et al.Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer[J].Future Oncol,2019,15(28):3233-3242.
[22] DUDANI S,MARGINEAN H,TANG P A,et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation[J].BMC Cancer,2019,19(1):664.
[23] WARD W H,GOEL N,RUTH K J,et al.Predictive value of leukocyte-and platelet-derived ratios in rectal adenocarcinoma[J].J Surg Res,2018,232(5):275-282.
[24] PARK I J,YOU Y N,AGARWAL A,et al.Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J].J Clin Oncol,2012,30(15):1770-1776.
[25] 徐莹莹,郭信伟,冀胜军,等.疗前预后营养指数对老年食管鳞癌放疗预后预测价值[J].中华放射肿瘤学杂志,2019,28(9):669-672.
[26] PENG J,ZHANG R,ZHAO Y,et al.Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage Ⅲ colon cancer[J].Chin J Cancer,2017,36(1):96.
[27] NOBLE F,HOPKINS J,CURTIS N,et al.The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer[J].Med Oncol,2013,30(3):596.
[28] GARCIA-MARTINEZ R,ANDREOLA F,MEHTA G,et al.Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure[J].J Hepatol,2015,62(4):799-806.
[29] PETRELLI F,BARNI S,COINU A,et al.The modified glasgow prognostic score and survival in colorectal cancer:a pooled analysis of the literature[J].Rev Recent Clin Trials,2015,10(2):135-141.
[30] 李涛,吕家华,郎锦义,等.恶性肿瘤放疗患者营养治疗专家共识[J].肿瘤代谢与营养电子杂志,2018,5(4):358-365.
[31] KRATZ F.Albumin as a drug carrier:design of prodrugs,drug conjugates and nanoparticles[J].J Control Release,2008,132(3):171-183.
[32] 王修身,张羲茜,习勉,等.食管鳞癌新辅助放化疗后淋巴细胞下降与病理反应相关性分析[J].中华放射肿瘤学杂志,2019,28(4):274-279.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 339490 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364